NLE Musculoskeletal Nursing — Degenerative, Inflammatory and Metabolic Bone DisordersStudy Notes

Osteoarthritis is a **degenerative, non-inflammatory (or low-inflammatory) 'wear-and-tear' disorder** in which articular cartilage progressively deteriorates, leading to bone rubbing on bone, the formation of bone spurs (osteophytes), and joint space narrowing. Unlike rheumatoid arthritis, OA is primarily a mechanical problem affecting individual joints rather than a systemic autoimmune disease. **Pathophysiology**: In OA, the protective hyaline cartilage that covers the bone ends breaks down over time due to aging, repetitive stress, obesity, and joint injury. As cartilage erodes, bone becomes exposed and develops reactive bone spurs. This process leads to joint pain, stiffness, and eventual loss of function. The disease is typically asymmetric, meaning it may affect one knee or hip but not the other. **Risk Factors**: - Age (most common in adults over 50 years old) - Obesity and excess body weight (especially affecting weight-bearing joints) - Repetitive joint use or occupational stress (e.g., construction workers, farmers) - Previous joint injuries or trauma - Female gender (particularly postmenopausal women) - Family history of OA - Sedentary lifestyle - Joint deformities or misalignment **Common Sites of Involvement**: - **Weight-bearing joints**: knees, hips, lumbar and cervical spine, ankles - **Non-weight-bearing joints**: distal interphalangeal (DIP) joints (Heberden's nodes) and proximal interphalangeal (PIP) joints (Bouchard's nodes) **Clinical Manifestations**: 1. **Pain**: Worse with activity and relieved by rest; typically improves after 15–30 minutes of rest 2. **Stiffness**: Brief (under 30 minutes), worst in the morning or after prolonged inactivity 3. **Joint deformities**: Heberden's nodes and Bouchard's nodes at the finger joints 4. **Crepitus**: Grinding sensation in the joint during movement (caused by exposed bone) 5. **Decreased range of motion**: Progressive loss of mobility 6. **Joint swelling**: Usually mild, caused by bony enlargement rather than inflammation 7. **Muscle weakness**: Around affected joints due to disuse 8. **NO systemic symptoms**: No fever, no weight loss, no fatigue (this distinguishes OA from RA) **Nursing Diagnosis Priority** (using NANDA-I and Maslow's Hierarchy): - **Acute Pain/Chronic Pain** (Safety and Comfort Needs) - **Impaired Physical Mobility** (Self-actualization Needs) - **Activity Intolerance** (Safety and Comfort Needs) - **Deficient Knowledge** regarding disease management and lifestyle modification (Cognitive Needs)

Rheumatoid arthritis is a **chronic, systemic, autoimmune, inflammatory disorder** in which the body's immune system mistakenly attacks the synovial membrane lining the joints. This leads to formation of a destructive tissue called **pannus**, which erodes cartilage and bone, causing progressive joint destruction and deformity. RA is not merely a joint problem—it is a whole-body disease affecting multiple organ systems. **Pathophysiology**: In RA, abnormal T and B lymphocytes infiltrate the synovial membrane, releasing inflammatory cytokines (tumor necrosis factor, interleukin-6) and enzymes that destroy articular cartilage and bone. The disease typically begins in small joints of the hands and feet and progresses symmetrically (bilaterally). The chronic inflammation also triggers systemic manifestations including malaise, fatigue, and constitutional symptoms. **Epidemiology**: - More common in women than men (3:1 ratio) - Usually onset between ages 30 and 50 years - Less common in Southeast Asian populations but increasingly prevalent in the Philippines due to changing lifestyles - Strong genetic component (HLA-DR4 positive) **Clinical Manifestations**: 1. **Joint manifestations**: - **Bilateral and symmetric** involvement (both hands affected equally, both feet affected equally) - Starts in small joints: hands, wrists, feet, ankles - Progresses to larger joints: elbows, knees, shoulders, hips - **Morning stiffness lasting more than 1 hour** (hallmark sign) - Pain and swelling worse in morning, may persist throughout day - Deformities: **ulnar deviation** (fingers point toward the ulnar side), **swan-neck deformity** (hyperextension at PIP joint, flexion at DIP joint), **boutonniere deformity** (flexion at PIP, hyperextension at DIP) 2. **Systemic manifestations**: - Fatigue and malaise - Low-grade fever (99–101°F / 37.2–38.3°C) - Unintentional weight loss - Anorexia - Generalized muscle aching 3. **Extra-articular manifestations** (involvement of organs outside joints): - **Rheumatoid nodules**: Firm, subcutaneous nodules on pressure points (elbows, fingers) in 20–30% of patients - **Anemia**: Chronic disease anemia - **Lymphadenopathy**: Enlarged lymph nodes - **Splenomegaly**: Enlarged spleen (Felty's syndrome when accompanied by neutropenia) - **Pericarditis and myocarditis**: Cardiac inflammation - **Pleural effusion and pulmonary fibrosis**: Lung involvement - **Sjögren's syndrome**: Dry eyes and dry mouth (comorbid autoimmune condition) - **Vasculitis**: Blood vessel inflammation causing skin ulcers, gangrene **Diagnostic Findings**: - **Elevated inflammatory markers**: ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) - **Positive rheumatoid factor (RF)**: Present in 70–80% of RA patients - **Positive anti-CCP (anti-cyclic citrullinated peptide) antibodies**: More specific than RF; present in early RA and highly predictive of joint damage - **X-ray findings**: Joint space narrowing, marginal erosions, osteopenia in early disease; progressive destruction in advanced disease - **MRI**: Shows soft tissue inflammation and early bone erosions **Nursing Diagnosis Priority** (using NANDA-I and Maslow's Hierarchy): - **Chronic Pain** (Safety and Comfort Needs) - **Fatigue** (Safety and Comfort Needs) - **Impaired Physical Mobility** (Self-actualization Needs) - **Ineffective Role Performance** (Self-actualization Needs) - **Deficient Knowledge** regarding disease-modifying therapy and medication adherence (Cognitive Needs)

The NLE frequently tests the distinction between OA and RA because these are the two most common arthritides in adults and their management differs significantly. Understanding the differences is essential for accurate nursing assessment and intervention planning. **Side-by-side Comparison**: | Feature | Osteoarthritis (OA) | Rheumatoid Arthritis (RA) | |---------|-------------------|-------------------------| | **Type** | Degenerative (mechanical wear) | Autoimmune/Inflammatory (systemic) | | **Symmetry** | Asymmetric (one side affected) | Symmetric (bilateral) | | **Joints Affected** | Large weight-bearing joints (knees, hips, spine) and DIP joints | Small joints (hands, wrists, feet, ankles) first, then larger joints | | **Onset** | Gradual (years) | Subacute to acute (weeks to months) | | **Age** | Usually >50 years (increasing with age) | 30–50 years (can occur at any age) | | **Gender** | Roughly equal; slightly more women | 3:1 female to male ratio | | **Morning Stiffness** | Brief (<30 minutes) | Prolonged (>1 hour, often 2–3 hours) | | **Pain Pattern** | Worse with activity, improves with rest | Throughout the day, pain and stiffness; may improve slightly with activity | | **Nodules** | Heberden's (DIP) and Bouchard's (PIP) nodes | Rheumatoid nodules (firm, on pressure points like elbows) | | **Systemic Symptoms** | Absent | Present (fatigue, fever, weight loss, malaise) | | **Laboratory Findings** | Normal ESR and CRP; negative RF and anti-CCP | Elevated ESR and CRP; positive RF and anti-CCP | | **X-ray** | Joint space narrowing, osteophytes, sclerosis | Marginal erosions, joint space narrowing, osteopenia | | **Prognosis** | Slow, progressive; joints may become severely deformed but function may remain relatively preserved | Progressive; without treatment, rapid joint destruction and deformity; significant functional impairment | | **Treatment Focus** | Acetaminophen, NSAIDs, heat/cold, weight loss, exercise | DMARDs (methotrexate anchor), NSAIDs, corticosteroids, biologic agents, balance rest with activity | **Memory Aid for Distinguishing OA from RA**: - **OA** = "One-sided" (Asymmetric), "Old" (older age), "Occasional" stiffness (under 30 min) - **RA** = "Rheumatoid" (autoimmune), "Reversed" (small joints first), "Reliably" stiff (>1 hour), "Rheumatoid factor positive" **Clinical Scenario for Differentiation**: A 60-year-old woman comes to the clinic with joint pain. To determine if it is OA or RA: 1. **Ask about morning stiffness**: If she says "About 20 minutes," this suggests OA. If she says "About 2 hours," this suggests RA. 2. **Examine the pattern**: If pain is asymmetric (right knee only), think OA. If symmetric (both hands and wrists equally), think RA. 3. **Check for systemic symptoms**: "Have you had fever or weight loss?" If no, think OA. If yes, think RA. 4. **Order labs**: Normal labs + clinical presentation = OA. Elevated ESR/CRP + positive RF/anti-CCP = RA. 5. **X-ray**: Osteophytes and joint space narrowing = OA. Marginal erosions = RA.

Nursing management of arthritis encompasses both acute flare management and long-term disease control. The goal is to reduce pain, maintain joint function, preserve mobility, and improve quality of life while preventing complications. **Management of Osteoarthritis**: 1. **Pharmacological Interventions**: - **First-line analgesia**: Acetaminophen (paracetamol) up to 3–4 g/day in divided doses - **NSAIDs** (ibuprofen, naproxen, meloxicam) for moderate pain and inflammation; use lowest effective dose for shortest duration to minimize GI and renal side effects - **Topical NSAIDs**: Diclofenac cream or gel on affected joints - **Intra-articular corticosteroid injections**: For single large joints with significant inflammation; provides temporary relief (weeks to months) - **Intra-articular hyaluronic acid**: May improve lubrication and reduce pain - **Muscle relaxants**: For associated muscle spasm 2. **Non-Pharmacological Interventions**: - **Heat therapy**: Warm packs, warm baths, paraffin wax dips for 15–20 minutes to relieve stiffness and reduce pain - **Cold therapy**: Ice packs for acute inflammation and swelling - **Joint protection**: Use of assistive devices (canes, walkers, knee braces, splints) to reduce stress on affected joints - **Rest and activity modification**: Balance rest with gentle activity; avoid strenuous activities that aggravate pain - **Weight reduction**: Essential for OA of weight-bearing joints; each kilogram of weight loss reduces knee OA progression - **Low-impact exercise**: Walking, swimming, water aerobics, tai chi to maintain muscle strength and joint mobility without excessive impact - **Range of motion exercises**: Gentle stretching and ROM exercises 3. **Patient Education**: - Proper body mechanics: bend at knees, not waist; avoid twisting; keep objects close to body when lifting - Sleep position: Use pillows to support joints; sleep on firm mattress - Home modifications: Raise chair and toilet seats, use grab bars, remove fall hazards - Nutrition: Emphasize anti-inflammatory foods (fish, berries, leafy greens); avoid obesity - Footwear: Supportive shoes with good cushioning **Management of Rheumatoid Arthritis**: 1. **Pharmacological Interventions**: a) **Disease-Modifying Antirheumatic Drugs (DMARDs)** — The Cornerstone of RA Treatment: - **Methotrexate**: The anchor DMARD; interferes with purine metabolism and immune function - Dosing: Usually 7.5–25 mg once weekly (given as oral tablets or subcutaneous injection) - Monitoring: Monthly CBC, liver function tests (ALT, AST, albumin), and renal function - Side effects: Bone marrow suppression, hepatotoxicity, stomatitis, gastrointestinal upset - **Critical nursing point**: Give **folic acid** (1 mg daily or 5 mg on weekdays) to reduce methotrexate toxicity - **Contraindication**: Teratogenic—counsel women of childbearing age to use reliable contraception - Avoid alcohol (increases hepatotoxicity) - Avoid concurrent use with other hepatotoxic drugs - **Other traditional DMARDs**: Sulfasalazine, hydroxychloroquine (often used in combination with methotrexate) b) **Biologic Disease-Modifying Agents** — For patients with inadequate response to methotrexate: - **TNF-alpha inhibitors**: Etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira) - **IL-6 inhibitors**: Tocilizumab - **B-cell inhibitors**: Rituximab - **Janus kinase (JAK) inhibitors**: Baricitinib, tofacitinib - **Critical nursing point**: These biologics significantly increase infection risk (TB, opportunistic infections); screen for active infections and TB before starting; counsel patients on infection prevention - Monitor for injection site reactions (with subcutaneous agents) - More expensive; access in Philippines may be limited in public sector c) **NSAIDs** — For symptomatic relief: - Provide anti-inflammatory and analgesic effects - Use alongside DMARDs, not as monotherapy - Monitor for GI upset; consider proton pump inhibitors for GI protection d) **Corticosteroids** — For short-term use: - Low-dose oral prednisolone (5–10 mg/day) or methylprednisolone for flares - Intra-articular injections for large joint inflammation - Not used as monotherapy; never replace DMARDs - Long-term use carries risks of osteoporosis, infection, hyperglycemia 2. **Non-Pharmacological Interventions**: - **Balance rest and activity**: During flares, rest is emphasized; during remission, gradually increase activity to maintain joint mobility and muscle strength - **Heat therapy**: Warm baths, heating pads for 15–20 minutes to reduce morning stiffness - **Cold therapy**: Ice packs for acute flare inflammation - **Joint protection**: Use of splints and braces to reduce stress on inflamed joints - **Gentle range of motion exercises**: Perform within tolerance; water therapy (hydrotherapy) is excellent - **Occupational therapy**: Adapt activities of daily living; use jar openers, adaptive utensils, long-handled devices - **Patient education on medication adherence**: Emphasize the critical importance of taking DMARDs consistently to achieve remission and prevent irreversible joint damage 3. **Nursing Interventions for RA Flares**: - Apply heat for 15–20 minutes to reduce stiffness - Ensure adequate rest; allow morning routine to take time - Provide analgesia before exercises or activities - Support psychologically; acknowledge fatigue and emotional impact - Encourage nutrition; address anorexia with small, frequent, nutrient-dense meals - Monitor for extra-articular manifestations (cardiac, pulmonary, systemic) 4. **Patient Education for RA**: - **Medication adherence**: Explain that DMARDs take 6–12 weeks to show benefit; consistency is critical - **Contraception**: If on methotrexate or biologics, use reliable contraception due to teratogenicity - **Infection prevention**: Avoid exposure to people with colds, flu, TB; maintain hygiene - **Activity pacing**: Balance activity with rest; use "energy conservation techniques" - **Support groups**: Encourage participation in RA support groups (available in Philippines through patient organizations) - **Follow-up care**: Regular visits to rheumatologist and lab monitoring **Comparison of Treatment Approach**: - **OA**: Symptomatic management (acetaminophen, NSAIDs, physical therapy); focus on preventing progression through lifestyle modification - **RA**: Disease-modifying therapy (DMARDs and biologics) to halt disease progression and achieve remission; combine with symptomatic management

Gout is an acute and chronic metabolic disorder of **purine metabolism** in which elevated serum uric acid (hyperuricemia) leads to deposition of **monosodium urate (MSU) crystals** in and around joints, causing acute inflammatory arthritis. Gout is the most common type of inflammatory arthritis in men and is increasingly common in the Philippines, likely due to Western dietary patterns and increased prevalence of metabolic syndrome. **Pathophysiology**: Purines (from DNA and RNA breakdown, and dietary sources) are metabolized to uric acid via the enzyme xanthine oxidase. Uric acid is normally excreted by the kidneys. When serum uric acid exceeds the saturation point (usually >6.8 mg/dL), monosodium urate crystals precipitate in joints and soft tissues. These crystals trigger an intense inflammatory response mediated by interleukin-1 (IL-1) activation, complement activation, and neutrophil infiltration into the joint. The acute attack is self-limited, lasting days to weeks, even without treatment. **Risk Factors for Gout**: 1. **Hyperuricemia** (serum uric acid >6.8 mg/dL): - **Overproduction of uric acid** (10% of hyperuricemia cases): - High purine diet (organ meats, seafood, red meat, alcohol) - Increased cell turnover (cancer, leukemia, psoriasis, chemotherapy) - Genetic enzyme defects (hypoxanthine-guanine phosphoribosyltransferase deficiency) - **Underexcretion of uric acid** (90% of hyperuricemia cases): - Chronic kidney disease (most common cause) - Diuretics (especially thiazides and loop diuretics) - Low-dose aspirin - Dehydration and volume depletion - Hyperparathyroidism - Metabolic syndrome and insulin resistance 2. **Demographic and lifestyle factors**: - Male sex (more common in men; women post-menopausal) - Age (typically after age 40 in men) - Obesity - Excessive alcohol consumption (especially beer) - High-purine diet - Dehydration - Recent surgery or acute illness (triggers flare) - Certain medications (thiazide diuretics, low-dose aspirin) **Clinical Manifestations**: **Acute Gout Attack**: - **Sudden onset** of severe joint pain, redness, warmth, and swelling (usually overnight) - **Most common site**: **Podagra** — the great toe (first metatarsophalangeal joint); also affects midfoot, ankles, knees, wrists, fingers - **Severity**: Exquisite tenderness; patient often cannot tolerate even light touch or weight of bed linens (a bed cradle or footboard is helpful) - **Duration**: Attack typically lasts 3–10 days without treatment; may resolve in 1–2 weeks even without therapy - **Systemic symptoms**: Low-grade fever, malaise (less severe than in RA or other systemic inflammatory conditions) - **Frequency**: Initial attacks are single; over time, attacks become more frequent and polarticular (multiple joints) **Chronic Gout**: - **Tophi**: Deposits of monosodium urate crystals forming firm nodules (usually on helix of ear, fingers, elbows, Achilles tendon); these are pathognomonic for chronic tophaceous gout - **Chronic arthropathy**: Progressive joint damage from repeated crystal deposition; resembles OA - **Uric acid kidney stones**: Risk of nephrolithiasis (uric acid stones) due to high uric acid excretion - **Chronic kidney disease**: Prolonged hyperuricemia can damage kidneys (gouty nephropathy) **Diagnostic Findings**: - **Serum uric acid level**: Elevated (>6.8 mg/dL); may be normal during acute attack due to acute phase response and reduced uric acid production - **Synovial fluid analysis** (gold standard for diagnosis): - Shows **needle-shaped, negatively birefringent monosodium urate crystals** - Crystals are intracellular (inside white blood cells) - Elevated WBC in synovial fluid (often 10,000–50,000) - Culture is negative (distinguishes gout from septic arthritis) - **X-ray findings**: In chronic gout, may show tophi (punched-out lesions) and joint destruction - **Imaging**: Ultrasound or DEXA may show evidence of urate deposits **Nursing Diagnosis Priority** (using NANDA-I and Maslow's Hierarchy): - **Acute Pain** (Safety and Comfort Needs) - **Impaired Mobility** (Self-actualization Needs) - **Deficient Knowledge** regarding diet, medications, and prevention of future attacks (Cognitive Needs)

Management of gout is divided into two phases: acute attack management (symptom relief) and chronic prevention (urate-lowering therapy). **Acute Gout Attack Management**: 1. **Colchicine**: - **Mechanism**: Inhibits neutrophil migration and IL-1 release; reduces inflammation within hours - **Dosing**: - Low-dose regimen (preferred): 1.2 mg orally, followed by 0.6 mg 1 hour later, then 0.6 mg three times daily for 2–3 days - Traditional high-dose regimen: 1 mg followed by 0.5 mg every 2 hours until relief or toxicity (now rarely used due to side effects) - **Side effects**: Nausea, vomiting, diarrhea, and abdominal cramps; these signal toxicity and dose should be reduced or stopped - **Efficacy**: Most effective when given within 24 hours of attack onset - **Nursing point**: Warn patient that diarrhea is expected but severe diarrhea with blood indicates toxicity - **Contraindications**: Severe renal or hepatic impairment - **Important**: In the Philippines, colchicine may not always be readily available in all healthcare facilities; NSAIDs or corticosteroids may be substituted 2. **Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)**: - **Examples**: Indomethacin, naproxen, meloxicam - **Dosing**: - Indomethacin: 50 mg three times daily initially, then taper over 7–10 days - Naproxen: 500 mg twice daily initially, then 250 mg twice daily - **Mechanism**: Inhibit COX enzymes, reducing prostaglandin-mediated inflammation - **Onset**: Faster than colchicine (within hours) - **Side effects**: GI upset, dyspepsia; consider GI protection with proton pump inhibitors - **Contraindications**: Severe renal disease, history of GI ulcer - **Preferred**: NSAIDs are often first-line in many settings, including Philippine hospitals 3. **Corticosteroids**: - **Indications**: For patients who cannot tolerate colchicine or NSAIDs (e.g., severe renal disease, GI ulcer, NSAID allergy) - **Dosing**: - Oral prednisolone: 30–40 mg daily for 5–7 days, then taper - Intra-articular injection: Triamcinolone acetonide 20–40 mg for monoarticular gout - **Onset**: Within 24–48 hours - **Note**: Less effective than colchicine or NSAIDs for acute attack 4. **Supportive Care During Acute Attack**: - **Rest**: Elevate and immobilize the affected joint - **Cold therapy**: Ice pack application for 15–20 minutes to reduce inflammation (some patients prefer heat) - **Joint protection**: Use a bed cradle or footboard to protect the foot from bed linens (light touch is extremely painful) - **Analgesics**: Acetaminophen for pain (NSAIDs preferred if tolerated) - **Fluid intake**: Encourage oral fluids (if not contraindicated by volume overload) to enhance uric acid excretion - **Strict bed rest** during acute flare period **Chronic Gout Management (Urate-Lowering Therapy)**: 1. **Allopurinol**: - **Mechanism**: Xanthine oxidase inhibitor; reduces uric acid production from purine breakdown - **Dosing**: Usually start 100 mg daily, increase by 100 mg every 2–3 weeks until serum uric acid is <6 mg/dL (target 5 mg/dL or lower); typical maintenance is 300 mg daily - **Onset**: Takes 2–3 weeks to lower serum uric acid; 2–3 months for tophi to regress - **Monitoring**: Monitor serum uric acid level; start low and go slow (gradual titration) to avoid paradoxical acute flares - **Critical nursing point**: **DO NOT START ALLOPURINOL DURING AN ACUTE ATTACK** — allopurinol lowers uric acid rapidly, and MSU crystal shedding can precipitate or worsen the current attack. Start allopurinol 2–4 weeks after an acute attack resolves. If starting allopurinol during chronic prophylaxis, give colchicine or NSAIDs concurrently for 3–6 months to prevent flares. - **Side effects**: - **Rash** (mild and dose-related) - **Severe hypersensitivity syndrome** (rare but serious): Fever, rash (exfoliative), hepatitis, renal failure, eosinophilia, vasculitis. **Stop allopurinol immediately** if this occurs; high mortality if not recognized. More common in patients with renal impairment and HLA-B*5801 genotype (more common in Asian populations, including Filipinos). - **Hepatotoxicity**: Elevated liver enzymes (rare) - **Nausea, GI upset**: Mild and usually resolve - **Monitoring parameters**: Baseline liver and renal function; monitor uric acid level every 2–5 weeks during titration 2. **Probenecid**: - **Mechanism**: Uricosuric agent; increases renal excretion of uric acid - **Dosing**: Start 250 mg twice daily, increase gradually to 500 mg twice daily or higher - **Efficacy**: Similar to allopurinol; lowers uric acid within 1–2 weeks - **Advantage**: Does not increase allopurinol metabolism (can be used with allopurinol in refractory gout) - **Disadvantages**: Less commonly used than allopurinol; increases risk of uric acid kidney stones - **Contraindications**: Severe renal disease (creatinine clearance <50 mL/min), history of uric acid stones, HLA-B*5801 positive (in some populations) 3. **Febuxostat**: - **Mechanism**: Non-purine xanthine oxidase inhibitor; more selective than allopurinol - **Dosing**: 40–80 mg daily - **Advantages**: Longer half-life (allows once-daily dosing); fewer drug interactions; less hyperuricemia-associated hypersensitivity syndrome - **Cost**: More expensive than allopurinol; limited access in Philippines - **Note**: May not be available in all Philippine healthcare settings **Dietary and Lifestyle Management (Critical for Prevention)**: 1. **Foods to Avoid** (high purine content): - **Organ meats**: Liver, kidney, sweetbreads (high purine content, especially liver) - **Red meat**: Beef, pork, lamb (moderate to high purine) - **Seafood**: Shellfish (shrimp, crab, lobster), sardines, anchovies, mackerel, tuna (high purine; small portion fish is acceptable) - **Alcohol**: Beer is particularly high in purine; spirits less so; wine moderate - **High-fructose foods and drinks**: Sugary soft drinks, fruit juices (fructose increases uric acid production) - **Purine-rich vegetables**: Asparagus, mushrooms, spinach (moderate; usually not a major concern if kidney function normal) 2. **Foods to Encourage**: - **Lean proteins**: Skinless poultry (chicken, turkey) in moderation - **Dairy products**: Low-fat milk, yogurt (protective effect against gout) - **Plant-based proteins**: Legumes are moderate in purine but have a protective net effect - **Cherries and cherry juice**: Anecdotal evidence suggests they lower uric acid; recommend if patient tolerates - **Coffee**: Some evidence of protective effect (2–3 cups daily) - **Vegetables**: Most vegetables are safe (except asparagus, mushrooms, spinach in excess) - **Whole grains and complex carbohydrates**: Encourage 3. **Lifestyle Modifications**: - **Hydration**: Drink 2–3 L of water daily to maintain urine output >2 L/day (helps flush uric acid and prevent stone formation) - **Weight management**: Gradual weight loss if overweight; **avoid crash dieting** (rapid weight loss raises uric acid levels and can precipitate attacks) - **Limit alcohol**: Especially beer; if patient drinks, limit to 1–2 standard drinks per day - **Avoid dehydration**: Ensure adequate fluid intake, especially in hot weather - **Regular exercise**: Low-impact activity (walking, swimming) to maintain fitness **Gout Nursing Care Plan** (Example): **Nursing Diagnosis**: Acute Pain related to inflammatory response to MSU crystal deposition as evidenced by severe joint pain, redness, swelling - **Goal**: Patient reports pain reduction to 3/10 within 4 hours; able to rest the affected joint - **Interventions**: 1. Administer colchicine or NSAIDs as ordered 2. Elevate and immobilize affected joint; place on pillows 3. Apply ice pack (wrapped in cloth) for 15–20 minutes every 2–3 hours 4. Use bed cradle to protect from weight of linens 5. Position for comfort; avoid moving joint 6. Provide quiet, cool environment 7. Monitor pain response; assess for relief in 2–4 hours 8. Administer additional analgesia as needed and ordered - **Evaluation**: Pain reduced; patient able to rest **Nursing Diagnosis**: Deficient Knowledge regarding dietary modifications and prevention of future attacks as evidenced by patient statement "I don't know what foods cause gout" - **Goal**: Patient verbalizes understanding of foods to avoid and accepts prescribed urate-lowering therapy within 2 days - **Interventions**: 1. Provide written list of foods to avoid (high-purine foods) 2. Discuss importance of hydration (2–3 L daily) 3. Explain allopurinol therapy: mechanism, importance of regular use, side effects to report 4. Emphasize: DO NOT START allopurinol during acute attack; wait 2–4 weeks 5. If starting allopurinol, give colchicine concurrently for 3–6 months to prevent paradoxical flares 6. Teach about weight loss (gradual, not crash diet) 7. Encourage limited alcohol, especially beer 8. Recommend follow-up uric acid level in 4–6 weeks - **Evaluation**: Patient able to list forbidden foods; demonstrates understanding of allopurinol timing and hydration; verbalizes commitment to lifestyle changes

Osteoporosis is a progressive **metabolic bone disease** characterized by **low bone mass and deterioration of bone microarchitecture**, leading to increased bone fragility and susceptibility to **pathologic fracture** (fracture from minimal trauma). Osteoporosis is called a "silent disease" because bone loss occurs without symptoms until a fracture occurs, often suddenly with minimal trauma. **Epidemiology in the Philippines**: - Increasing prevalence, especially in postmenopausal women - WHO estimates that 1 in 3 women over age 50 and 1 in 5 men over age 50 will suffer an osteoporotic fracture - Related to increased Western lifestyle (sedentary, low calcium intake), increased life expectancy, and population aging **Pathophysiology**: Bone is a dynamic tissue constantly remodeling through the balance of bone formation (by osteoblasts) and bone resorption (by osteoclasts). In osteoporosis, this balance is disrupted—bone resorption exceeds bone formation, resulting in net bone loss. Estrogen deficiency (postmenopausal state) accelerates bone resorption by increasing osteoclast activity and lifespan. Other factors (age, inadequate calcium/vitamin D, physical inactivity, smoking) also contribute. **Risk Factors for Osteoporosis**: 1. **Non-modifiable risk factors**: - **Female sex**: Women have lower peak bone mass than men and lose bone rapidly after menopause - **Age**: Bone loss accelerates after age 60 (women) and 75 (men) - **Ethnicity**: Highest risk in white (Caucasian) women; lower risk in African and Asian women (but Asians still at risk) - **Small body frame** (lean, thin build): Lower peak bone mass - **Family history** of osteoporosis - **Postmenopausal state**: Estrogen deficiency accelerates bone loss 2. **Modifiable risk factors**: - **Low calcium intake** (<800 mg/day) - **Low vitamin D intake or deficiency** (vitamin D required for calcium absorption) - **Sedentary lifestyle**: Lack of weight-bearing exercise - **Smoking**: Impairs bone formation and increases fracture risk - **Excessive alcohol consumption** (>3 drinks/day for men, >2 drinks/day for women) - **Excessive caffeine intake**: May increase urinary calcium loss (though effect is modest) - **High sodium diet**: Increases urinary calcium excretion - **Medications**: Chronic corticosteroid use (prednisone), anticonvulsants, excess thyroid hormone, aromatase inhibitors - **Medical conditions**: Chronic kidney disease (reduced vitamin D activation), malabsorption disorders (celiac disease, inflammatory bowel disease), hyperparathyroidism, hyperthyroidism, multiple myeloma, COPD - **Hormonal factors**: Estrogen deficiency, testosterone deficiency in men **Clinical Manifestations**: In early to moderate osteoporosis, patients are often **asymptomatic**. Manifestations typically appear after a fracture. 1. **Before fracture**: - Usually no symptoms (silent disease) - May report vague back pain 2. **After fracture** (common sites): - **Hip fracture** (femoral neck or intertrochanteric): Fall with inability to bear weight; severe hip pain; limb appears shortened and externally rotated - **Vertebral compression fractures** (thoracic and lumbar spine): Sudden back pain (with or without trauma); progressive kyphosis (forward curvature of spine, "dowager's hump"); loss of height (can lose 3–5 inches over years); thoracic kyphosis can impair lung function and cause dyspnea - **Wrist fracture** (Colles' fracture): Fall on outstretched hand; classic fracture of distal radius 3. **Chronic effects of vertebral fractures**: - Chronic back pain and muscle spasm - Pulmonary dysfunction (restrictive lung disease from kyphosis) - Gastrointestinal effects (early satiety from kyphosis) - Reduced mobility and quality of life **Diagnostic Testing**: 1. **DEXA (Dual-Energy X-ray Absorptiometry) Scan**: - **Gold standard** for osteoporosis diagnosis - Measures bone mineral density (BMD) at hip, spine, and forearm - Calculates **T-score**: Compares patient's BMD to healthy 30-year-old of same sex - **T-score ≥ −1**: Normal bone density - **T-score between −1 and −2.5**: Osteopenia (low bone mass; not yet osteoporosis but increased fracture risk) - **T-score ≤ −2.5**: Osteoporosis - **T-score ≤ −2.5 with fracture**: Severe osteoporosis (established osteoporosis) - **Interpretation**: Each 1.0 decrease in T-score increases 10-year fracture risk by approximately 3-fold 2. **Additional Tests**: - **FRAX (Fracture Risk Assessment Tool)**: WHO tool predicting 10-year fracture probability; helps determine who needs treatment - **Serum calcium and phosphate**: Usually normal in osteoporosis (unless underlying disease) - **Alkaline phosphatase**: May be elevated if healing from fracture - **Vitamin D level** (25-hydroxyvitamin D): Assess for deficiency; goal is 30–100 ng/mL - **Thyroid-stimulating hormone (TSH)**: Rule out hyperthyroidism or excess thyroid hormone replacement - **Renal function**: Important for vitamin D metabolism and calcium handling - **Bone markers** (CTX, P1NP): May be used to assess bone turnover and response to therapy (not routinely used for diagnosis) **Screening Recommendations** (Updated): - **All postmenopausal women age 50 and older** should be screened - **Men age 70 and older** - **Younger postmenopausal women and women age 50–70** with clinical risk factors - **Adults with clinical risk factors** at any age **Nursing Diagnosis Priority** (using NANDA-I and Maslow's Hierarchy): - **Risk for Trauma: Fracture** (Safety Needs) - **Risk for Falls** (Safety Needs) - **Chronic Pain** (Comfort Needs) [if fractures have occurred] - **Deficient Knowledge** regarding calcium, vitamin D, exercise, and fall prevention (Cognitive Needs)

Osteoporosis management focuses on **slowing bone loss, increasing bone formation, and preventing fractures**. Approach is multifaceted, combining pharmacological and non-pharmacological strategies. **Non-Pharmacological Interventions** (Foundation of Management): 1. **Calcium Supplementation**: - **Recommended intake**: - **Women age 51+**: 1200 mg/day - **Men age 51–70**: 1000 mg/day - **Men age 71+**: 1200 mg/day - **Postmenopausal women**: 1200 mg/day - **Dietary sources** (preferred): - **Milk and dairy**: 1 cup milk = 300 mg calcium; 1 cup yogurt = 300 mg; 1 oz cheese = 200 mg - **Green leafy vegetables**: Bok choy, collard greens, broccoli (note: spinach is high in oxalates which bind calcium) - **Fortified foods**: Fortified soy milk, orange juice, cereals - **Fish with bones**: Canned salmon, sardines (if bones are eaten) - **Supplements** (if dietary intake insufficient): - **Calcium carbonate**: Best absorbed with food; 40% elemental calcium - **Calcium citrate**: Better absorbed on empty stomach; 21% elemental calcium; preferred in patients with low stomach acid - **Dosing**: Divided doses (e.g., 600 mg twice daily) are better absorbed than single large dose - **Side effects**: Constipation, bloating; take with adequate fluids - **Interactions**: Tetracycline antibiotics, iron supplements, and fluoroquinolones should be taken 2 hours apart from calcium - **In Philippines context**: Dairy may be less available/affordable in rural areas; encourage non-dairy sources (leafy greens, fortified foods, canned fish with bones); calcium-fortified rice and other local staples may help 2. **Vitamin D Supplementation**: - **Recommended intake**: - **Age 51–70 years**: 600–800 IU/day (15–20 mcg/day) - **Age 71+ years**: 800 IU/day (20 mcg/day) - **Higher doses** (1000–2000 IU) if deficient (25-hydroxyvitamin D <30 ng/mL) - **Dietary sources**: - **Fatty fish**: Salmon, mackerel, sardines (rich in vitamin D) - **Egg yolks**: Contain small amounts - **Fortified milk and cereals** - **Synthesis**: Sun exposure (15–30 minutes daily, 3–4 times per week) on exposed skin (face, arms, legs) promotes vitamin D synthesis - **Supplementation forms**: - **Vitamin D2** (ergocalciferol): Plant-derived; less effective - **Vitamin D3** (cholecalciferol): Animal-derived; more effective; preferred - **Monitoring**: Check serum 25-hydroxyvitamin D level; goal is 30–100 ng/mL (75–250 nmol/L) - **Note in Philippines**: Tropical location (near equator) provides abundant sun exposure, but may be insufficient for populations with dark skin pigmentation or high SPF sunscreen use 3. **Weight-Bearing and Muscle-Strengthening Exercise**: - **Mechanism**: Mechanical stress on bones stimulates osteoblast activity and bone formation; muscle strength reduces fall risk - **Recommended**: 150 minutes of moderate-intensity aerobic activity per week + resistance training 2 days/week (per WHO guidelines) - **Types of weight-bearing exercise**: - **Walking**: Low-impact, accessible, can do daily; recommend 30–45 minutes, 5 days/week - **Dancing**: Enjoyable, weight-bearing, and social - **Jogging/running**: Higher impact; may not be suitable if already osteoporotic (fracture risk) - **Stair climbing**: Good weight-bearing activity - **Tai chi**: Gentle, improves balance, reduces falls - **Resistance training**: - **Weights, resistance bands, or body weight exercises**: Enhance muscle strength around joints - **Examples**: Squats, lunges, step-ups, push-ups, wall push-ups - **Frequency**: 2 days/week, with 1 day rest between sessions - **Avoid**: High-impact activities (jumping, running) if osteoporosis is severe; risk of fracture - **Balance training**: Standing on one leg, heel-to-toe walking; improves proprioception and reduces falls - **Duration to see effect**: 6–12 months of consistent exercise to see measurable increase in bone density 4. **Fall Prevention** (Critical, as fracture is the feared outcome): - **Home safety**: - Remove loose rugs and cords - Install grab bars in bathroom (near toilet, shower/tub) - Ensure adequate lighting (especially at night) - Arrange furniture to clear pathways - Use non-slip shoes with good traction - Install handrails on stairs - **Assistive devices**: - Canes, walkers for balance or mobility assistance - Shock-absorbing footwear - **Vision and hearing**: - Regular eye exams; ensure glasses are current - Address hearing loss (hearing aid if needed) - **Medication review**: - Identify medications that increase fall risk (sedatives, antihypertensives causing dizziness, etc.) - Adjust as needed - **Physical activity**: Maintain muscle strength and balance with exercise - **Vision and proprioception**: Regular assessment 5. **Lifestyle Modifications**: - **Smoking cessation**: Smoking impairs bone formation; cessation improves bone health - **Limit alcohol**: Excessive alcohol (>2–3 drinks/day) impairs bone metabolism - **Limit caffeine**: Excessive caffeine (>400 mg/day) increases urinary calcium loss; recommend <3 cups coffee/day - **Reduce sodium**: High sodium increases urinary calcium excretion; recommend <2300 mg/day - **Maintain healthy body weight**: Avoid both obesity and excessive thinness; BMI 18.5–24.9 is optimal - **Avoid crash dieting**: Rapid weight loss accelerates bone loss **Pharmacological Interventions**: 1. **Bisphosphonates** (First-Line Pharmacotherapy): - **Mechanism**: Inhibit osteoclastic bone resorption; slow bone loss and may modestly increase bone density - **Efficacy**: Reduce fracture risk by 50–70% (both vertebral and hip) - **Types**: - **Alendronate** (Fosamax): 70 mg once weekly or 10 mg daily - **Risedronate** (Actonel): 35 mg once weekly or 5 mg daily - **Ibandronate** (Boniva): 150 mg once monthly - **Zoledronic acid** (Aclasta): 5 mg IV once yearly - **Administration** (CRITICAL FOR NURSING): - **Oral bisphosphonates** (alendronate, risedronate, ibandronate): - Take on **empty stomach in the morning** (30–60 minutes before food or other medications) - **Take with a full glass of PLAIN WATER ONLY** (not mineral water, juice, coffee, milk, or other beverages) - **Remain upright** (sitting or standing) for **at least 30 minutes afterward** (some sources recommend 60 minutes for ibandronate) - Do not eat, drink (except water), or take other medications for 30 minutes - **Reason**: Bisphosphonates can cause esophageal irritation and erosive esophagitis if they come in contact with esophageal mucosa; remaining upright allows the drug to pass into the stomach and be absorbed - **IV bisphosphonates** (zoledronic acid): Given as annual infusion; no dietary restrictions - **Side effects**: - **Common**: GI upset (nausea, dyspepsia, diarrhea, constipation) - **Serious but rare**: - **Osteonecrosis of the jaw** (ONJ): Especially with long-term IV bisphosphonates; risk increases after 3–5 years. Maintain good dental hygiene; avoid dental procedures if possible. - **Atypical femoral fractures**: After long-term use (>5 years); subtrochanteric stress fractures (rare) - **Monitoring**: Renal function before starting (contraindicated if creatinine clearance <30 mL/min); serum calcium and magnesium; assess adherence - **Duration**: Bisphosphonates are typically continued indefinitely; after 5 years, consider a "drug holiday" (1–2 years off) in some patients with stable bone density, then resume if density declines - **Efficacy in Philippines context**: Bisphosphonates are available in major hospitals and private clinics; however, cost may limit access for patients in public sector 2. **Hormone Replacement Therapy (HRT)**: - **Mechanism**: Estrogen replacement slows bone loss - **Efficacy**: Reduces fracture risk by 30–40% - **Current use**: Limited due to increased risk of breast cancer, stroke, and VTE with long-term HRT (from Women's Health Initiative study) - **Current indication**: Short-term use (3–5 years) in early postmenopausal women with moderate osteoporosis; not first-line for osteoporosis alone - **Note**: Rarely initiated solely for osteoporosis; reserved for women with significant menopausal symptoms 3. **Selective Estrogen Receptor Modulators (SERMs)**: - **Example**: Raloxifene - **Mechanism**: Estrogen agonist in bone; antagonist in breast tissue - **Efficacy**: Reduces vertebral fracture risk by ~30%; less effective for hip fracture - **Advantage**: Reduces breast cancer risk (unlike HRT) - **Disadvantage**: Does not help menopausal hot flashes - **Side effects**: VTE risk (similar to HRT) - **Use**: Second-line option; not as effective as bisphosphonates 4. **Denosumab**: - **Mechanism**: Monoclonal antibody against RANKL; inhibits osteoclast formation - **Efficacy**: Efficacy similar to bisphosphonates in reducing fracture risk - **Dosing**: 60 mg subcutaneous injection every 6 months - **Advantages**: No special administration requirements (unlike oral bisphosphonates); may be better tolerated GI-wise - **Disadvantages**: More expensive than alendronate; requires repeat injections - **Side effects**: Similar to bisphosphonates; risk of osteonecrosis of jaw and atypical fractures (less common than with bisphosphonates) - **Availability in Philippines**: Available in major centers; cost is higher 5. **Parathyroid Hormone Analogs** (Anabolic Agents): - **Example**: Teriparatide (recombinant PTH 1–34) - **Mechanism**: Stimulates osteoblast activity (bone formation) - **Efficacy**: Most effective; reduces fracture risk by 65–70% (both vertebral and nonvertebral) - **Indication**: Severe osteoporosis with multiple fractures; increased fracture risk - **Dosing**: 20 mcg subcutaneous injection daily (maximum 2 years of therapy) - **Advantage**: Anabolic (builds bone); different mechanism than bisphosphonates - **Disadvantage**: Expensive; requires daily injections; long-term safety data limited - **Monitoring**: Serum calcium and uric acid; contraindicated in patients with history of bone metastases or radiation to skeleton - **Availability in Philippines**: Very limited; available only in major tertiary centers; very expensive **Treatment Algorithm** (WHO/Osteoporosis Foundation Recommendations): 1. **Diagnose** osteoporosis (DEXA T-score ≤ −2.5) 2. **Assess fracture risk** (FRAX tool) 3. **Initiate bone health basics**: Calcium, vitamin D, exercise, fall prevention 4. **Start pharmacotherapy** if: - T-score ≤ −2.5 anywhere (spine, hip, forearm) - T-score −1.0 to −2.5 with FRAX 10-year major osteoporotic fracture probability ≥20% or hip fracture probability ≥3% - History of hip or vertebral fracture 5. **First-line drug**: Bisphosphonate (alendronate, risedronate, or zoledronic acid) 6. **Monitor**: Bone density DEXA every 1–2 years; assess adherence; evaluate treatment response 7. **Switch agents** if inadequate response or intolerance **Filipino-Specific Considerations**: - Access to bisphosphonates may be limited in rural public sector; advocate for generic alendronate (more affordable than branded products) - Emphasis on cost-effective interventions: exercise, dietary calcium (leafy greens, fortified rice, canned fish), sun exposure for vitamin D - Community health nurses should educate on fall prevention and osteoporosis awareness in primary care settings - Coordination with private sector (where bisphosphonates are more readily available) for uninsured or low-income patients

Osteomyelitis is an **acute or chronic infection of the bone**, usually caused by **bacteria**, but occasionally by fungi or other organisms. It is a serious condition that can result in significant morbidity (chronic pain, impaired function) and, if untreated, can lead to sepsis, permanent disability, and even death. **Epidemiology**: - More common in developing countries and areas with high trauma rates (Philippines included) - Can occur at any age but more common in children (who have higher long bone blood flow) and elderly - More common in males than females - Often associated with IVDU (intravenous drug use), diabetes, immunocompromise, and open fractures **Pathophysiology**: Bacteria reach bone via one or more routes: 1. **Hematogenous spread** (bloodstream)—most common route: - Bacteria enter from a distant infection site (urinary tract infection, pneumonia, infected wound, dental abscess) - Settle in bone, particularly in areas of slowed blood flow (metaphysis of long bones in children, vertebrae in adults) - Establish infection within bone medullary cavity and periosteum 2. **Direct inoculation**: - Open fractures (bone exposed to environment) - Surgical procedures on bone (open reduction, hardware placement) - Puncture wounds (especially foot punctures through sneaker, contaminated) 3. **Contiguous spread**: - From adjacent soft tissue infection (e.g., cellulitis spreading to bone) - From surgical site infection Once established, bacteria multiply and trigger inflammatory response. Pus accumulates and increases intramedullary pressure, potentially compromising blood flow to bone, leading to **necrosis**. Dead bone is called **sequestrum**; the new bone that forms around it is **involucrum**. Formation of a sinus tract (abnormal channel from bone surface to skin) results in drainage. **Causative Organisms**: - **Staphylococcus aureus**: Most common (50–80% of cases), both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) - **Streptococcus pyogenes**: Second most common - **Gram-negative organisms**: Pseudomonas, E. coli (especially in elderly, immunocompromised) - **Mycobacterium tuberculosis**: TB osteomyelitis (less common but important in Philippines and areas with high TB prevalence) - **Atypical organisms**: Fungi (Aspergillus, Candida) in immunocompromised patients - **Polymicrobial infections**: Multiple organisms, common in open fractures and surgical infections **Clinical Manifestations**: **Acute Osteomyelitis**: - **Bone pain**: Localized, constant, severe, worse with weight-bearing or movement - **Swelling**: Around affected bone - **Erythema and warmth**: Over affected area - **Tenderness**: Exquisite point tenderness over infected bone - **Fever**: High-grade fever (38.5–39.5°C or 101–103°F), chills - **Malaise and fatigue**: Systemic signs of infection - **Functional impairment**: Loss of function of affected limb; child refuses to bear weight or move limb ("pseudo-paralysis") - **Drainage**: May form sinus tract with purulent drainage (later in disease) **Chronic Osteomyelitis**: - **Chronic pain**: Often milder than acute phase but persistent - **Draining sinus**: Purulent or serosanguineous drainage, often with foul odor - **Recurrent flares**: Periods of acute exacerbation interspersed with quiescent periods - **Bone deformity**: From repeated remodeling and scar tissue - **Pathologic fracture**: Weakened bone may fracture with minimal trauma - **Limited range of motion**: From scarring and contractures - **Constitutional symptoms**: May be absent between flares **Complications**: - **Sepsis and bacteremia**: Spread of infection to bloodstream; can lead to septic shock - **Chronic osteomyelitis**: If inadequately treated acutely - **Pathologic fracture**: From weakened bone - **Permanent disability**: From joint involvement (if infection extends to joint space, causing septic arthritis) or chronic pain and dysfunction - **Amputation**: In severe cases with uncontrolled infection or massive bone necrosis - **Fistula formation**: Sinus tract connecting bone to skin - **Subperiosteal abscess**: Collection of pus under periosteum - **Adjacent soft tissue infection**: Cellulitis, abscess **Diagnostic Findings**: 1. **Blood cultures**: Positive in 50% of acute hematogenous osteomyelitis; draw before antibiotics 2. **Laboratory findings**: - **Elevated WBC**: Usually >11,000 (but may be normal in chronic infection) - **Elevated ESR and CRP**: Both elevated, CRP more specific for acute inflammation - **Positive culture from bone or pus**: Definitive diagnosis; culture from infected bone or abscess fluid; identifies organism and antibiotic sensitivities 3. **Imaging**: - **X-ray**: May show bone lucency (dark areas from resorption), periosteal elevation, or sequestra (dead bone). Early osteomyelitis may not show radiographic changes (changes appear after 7–10 days). In chronic osteomyelitis, may show involucrum (new bone formation around sequestrum). - **MRI**: Most sensitive and specific; shows bone marrow edema, abnormal signal intensity, and soft tissue involvement; useful for early diagnosis when X-ray is negative - **CT**: Used to delineate extent of disease and guide surgical debridement - **Technetium-99m bone scan**: Shows increased uptake in infected bone; useful for detecting multiple sites - **Ultrasound**: May show soft tissue swelling and abscess (useful in children without radiation) 4. **Bone biopsy**: May be performed for culture if diagnosis unclear or to identify unusual organisms **Nursing Diagnosis Priority** (using NANDA-I and Maslow's Hierarchy): - **Risk for Infection/Sepsis** (Safety Needs) - **Acute Pain** (Comfort Needs) - **Hyperthermia** (Safety Needs) - **Impaired Mobility** (Self-actualization Needs) - **Risk for Deficient Fluid Volume** (if fever present) (Physiologic Needs) - **Deficient Knowledge** regarding IV antibiotic therapy and long-term follow-up (Cognitive Needs)

Osteomyelitis nursing care is complex and prolonged, often spanning weeks to months. The nurse plays a critical role in antimicrobial stewardship, pain management, infection prevention, and psychosocial support. **Acute Phase Management**: 1. **Infection Control and Antibiotic Therapy**: - **IV access**: Ensure reliable IV access; consider central line (PICC—peripherally inserted central catheter, or Hickman catheter) for long-term antibiotics at home - **Antibiotic administration**: - Administer IV antibiotics on strict schedule; use timer to ensure doses are timed appropriately - Monitor infusion site for phlebitis, infiltration, extravasation - Check antibiotic compatibility with other medications and IV fluids - Document antibiotic name, dose, time, route, and patient tolerance - **Microbiological monitoring**: - Track culture results and sensitivities; inform physician of any new culture results - Educate patient about importance of antibiotic completion even if patient feels better - **Fever management**: - Monitor temperature every 4 hours (or more frequently if high fever) - Antipyretics (acetaminophen, ibuprofen) as ordered - Cool compress or tepid sponging if needed - Ensure adequate hydration (IV or oral) to prevent dehydration from fever 2. **Pain Management**: - **Assess pain** using pain scale; use consistent assessment method - **Analgesics**: - Administer as ordered before movement, physical therapy, or dressing changes - NSAIDs (ibuprofen, naproxen) for inflammation and pain - Opioids (morphine, oxycodone) for severe pain; monitor for constipation - Note: Avoid NSAIDs if patient has renal compromise (common with sepsis) - **Non-pharmacological methods**: - Positioning: Immobilize affected limb with pillows, splints, or sling - Elevation: Keep affected limb elevated to reduce swelling and improve comfort - Heat/cold therapy: Gentle application (if not contraindicated) - Relaxation techniques: Deep breathing, guided imagery, music - **Pain behavior assessment**: Assess for pain-related dysfunction; may limit mobility even after infection controlled 3. **Immobilization and Mobility**: - **Acute phase**: Complete rest and immobilization of affected limb - **Use supportive devices**: Splints, slings, casts as indicated - **Positioning**: Change position every 2 hours to prevent pressure ulcers; maintain neutral alignment - **Passive range of motion**: Gentle ROM exercises to unaffected joints to prevent stiffness - **Prevent contractures**: Position joints in functional alignment - **Complications to prevent**: DVT (use sequential compression devices, encourage ankle exercises), skin breakdown (use pressure-relieving mattress) 4. **Wound and Drain Care** (if surgical drainage present): - **Dressing changes**: Perform using aseptic technique; frequency depends on drainage amount - **Document drainage**: Note color, amount, odor, type (purulent, serosanguineous, serous) - **Drain management**: Ensure patency; empty drain reservoir daily; monitor for blockage - **Odor control**: Change dressing frequently; use odor-eliminating products if needed - **Skin care around drain**: Keep skin clean and dry; monitor for maceration or irritation - **Hand hygiene**: Crucial before and after wound care to prevent cross-infection 5. **Nutrition**: - **Assess nutritional status**: Height, weight, recent weight loss - **Encourage high-protein diet**: For bone healing and immune function; recommend 1.5–2 g/kg/day - **Vitamin C**: Supports collagen synthesis and immune function - **Calcium and vitamin D**: Support bone healing - **Small, frequent meals**: If appetite reduced due to fever or illness - **Supplements**: Consider if dietary intake inadequate - **Ensure adequate hydration**: 2–3 L/day (unless contraindicated) 6. **Psychological Support**: - **Acknowledge emotional impact**: Long-term hospitalization or frequent outpatient visits; chronic pain; risk of amputation (in severe cases) - **Provide information**: Explain disease process, treatment plan, expected duration - **Involve family**: Include in care planning and education - **Assess for depression/anxiety**: Common in patients with chronic infection; refer to mental health if needed - **Encourage coping**: Support groups, social activities within limitations - **Occupational therapy referral**: To help maintain function and independence **Discharge and Home Management**: 1. **IV Antibiotic Therapy at Home**: - **Home health coordination**: Arrange for home health nurse to administer IV antibiotics if applicable - **Patient and family education**: - How to access central line or peripheral IV - Signs and symptoms of line infection or problems (redness, swelling, warmth, discharge, pain) - Flush protocol for central lines - Dressing change technique (if patient or family will do this) - **Adherence**: Emphasize importance of completing full course even if patient feels better - **Follow-up appointments**: Schedule with infectious disease specialist and orthopedic surgeon 2. **Activity and Mobility**: - **Gradual progression**: As pain decreases and infection resolves, gradually increase activity - **Weight-bearing**: As ordered by physician; may use crutches or walker initially - **Physical therapy referral**: For rehabilitation and strengthening - **Avoid strenuous activity**: Until cleared by physician; risk of relapse if activity resumed too quickly 3. **Infection Prevention**: - **Hand hygiene**: Teach proper technique to patient and family - **Avoid crowds**: Reduce exposure to infections while immunity is compromised - **Nutrition**: Continue focus on adequate intake - **Hygiene**: Proper showering technique if wound is present; waterproof dressing if needed 4. **Wound Care at Home**: - **Dressing supplies**: Provide with sterile supplies, or arrange for delivery - **Signs of infection to report**: Increasing pain, fever, pus, spreading redness, foul odor, wound not healing - **Aseptic technique**: Teach patient or family; demonstrate and assess return demonstration 5. **Monitoring and Follow-Up**: - **Laboratory values**: Schedule repeat blood cultures if fever persists; ESR/CRP to assess inflammation resolution - **Imaging**: Follow-up X-ray or MRI to document healing (usually after several weeks of antibiotics) - **Duration of therapy**: - **IV antibiotics**: Typically 4–6 weeks (depending on severity, organism, and response) - **Oral antibiotics**: May continue for additional weeks after IV therapy concludes - **Total duration**: Can extend to 8–12 weeks or longer for severe infection - **Physician visits**: Regular follow-up with infectious disease specialist and orthopedic surgeon 6. **Patient Education** (Critical for Compliance): - **Disease explanation**: Osteomyelitis is serious; untreated or inadequately treated it can lead to sepsis, amputation, or death - **Antibiotic importance**: Take every dose as scheduled for the full course; don't stop early even if feeling better - **Potential side effects**: Report any new symptoms (rash, diarrhea, nausea) - **Signs to report immediately**: Fever, increased pain, worsening swelling, spreading redness, new drainage, faintness - **Lifestyle modifications**: Adequate rest, nutrition, hygiene, smoking cessation if applicable - **Return to work**: Discuss realistic timeline based on severity; full recovery may take months 7. **Community Health Coordination** (Particularly in Philippines): - **BHW coordination**: Barangay Health Worker may assist with patient monitoring and compliance in rural areas - **Rural health center referral**: If patient discharged from hospital, local health center should be informed for ongoing monitoring - **Medication access**: Ensure patient can afford antibiotics for full course; assist with social services if needed - **Transportation**: Address barriers to follow-up appointments **Complications Monitoring**: - **Sepsis**: Monitor for signs (fever, tachycardia, hypotension, altered mental status); report immediately - **Chronic osteomyelitis**: If acute phase not adequately treated; patient may have recurrent flares - **Pathologic fracture**: With weakened bone; protect from trauma; ensure adequate calcium and vitamin D - **Amputation**: In uncontrolled infections or massive necrosis; requires psychosocial support and rehabilitation

Total hip replacement (THR), also called total hip arthroplasty, is a surgical procedure in which the diseased hip joint (femoral head and acetabulum) is replaced with prosthetic components. It is one of the most successful orthopedic surgeries, providing excellent pain relief and functional improvement, particularly in patients with severe osteoarthritis, rheumatoid arthritis, hip fracture, or avascular necrosis. The critical NLE content focuses on **hip precautions** — a strict set of movement restrictions designed to prevent **prosthetic dislocation**. **Indications for Total Hip Replacement**: - End-stage osteoarthritis (OA) of the hip - Severe rheumatoid arthritis - Femoral neck fracture (especially in elderly) - Avascular necrosis of femoral head - Severe hip dysplasia - Ankylosing spondylitis with hip involvement **Pathophysiology of Dislocation Risk**: The hip is a ball-and-socket joint. The femoral head (ball) normally sits within the acetabulum (socket). After hip replacement, the prosthetic femoral head must remain centered in the prosthetic acetabulum. If the hip is flexed beyond 90 degrees, adducted past midline, or internally rotated, the femoral head can slide out of the socket (dislocate). Dislocation is most common in the first 6–8 weeks post-operatively, when soft tissues (capsule, muscles) are still healing and cannot hold the prosthesis firmly. Risk of dislocation decreases over time as the joint capsule matures (usually by 3 months, joints are relatively stable). **Critical Hip Precautions** (Must Know for NLE): These are the **three fundamental rules** to prevent dislocation: **1. DO NOT FLEX THE HIP MORE THAN 90 DEGREES:** - **Rationale**: Excessive flexion can dislocate the prosthesis - **Clinical implications**: - Use a **raised toilet seat** (seat height 45–50 cm / 18–20 inches) — standard toilet height is too low - Avoid **low chairs and sofas** — if patient sits in a low chair, the hip may flex more than 90 degrees - When sitting, keep knees below hip level (use a pillow under thighs if needed) — knees should not be higher than hips - **Avoid bending forward** to reach feet, dress lower body, or pick up objects from the floor - Patient should not lie down with hips and knees bent (as in fetal position) - When in bed: keep the head of bed elevated (semi-Fowler position, at least 30–45 degrees) - Use a **hip abduction pillow** between legs to prevent flexion and adduction **2. DO NOT ADDUCT THE LEG PAST THE MIDLINE:** - **Rationale**: Adduction (moving leg toward midline) combined with flexion can cause dislocation - **Clinical implications**: - **Keep legs apart**: An abduction angle of at least 10–15 degrees (slightly apart) - **Do NOT cross the legs**: This is perhaps the most important rule; crossing legs severely adducts the hip - Use an **abduction pillow** or wedge between legs at all times: - When sitting - When lying in bed (between the knees) - When sleeping - When standing (if possible) - When turning in bed: keep a pillow between legs to maintain abduction - Patient should sleep **supine (on back) or on the unaffected side** ONLY (not on the operated side); if on unaffected side, maintain pillow between legs - Avoid sitting cross-legged - When walking with crutches or walker, keep legs slightly apart **3. DO NOT INTERNALLY ROTATE THE HIP:** - **Rationale**: Internal rotation (toes pointing inward) combined with flexion or adduction can dislocate the prosthesis - **Clinical implications**: - Keep **toes pointing forward or slightly outward** (external rotation) - Use an **external rotation pillow** or footboard to maintain toes pointing outward - Avoid positions where toes point inward - When lying in bed, place pillow under the knee and ankle to support external rotation - When walking, ensure patient walks with toes forward **Signs and Symptoms of Hip Dislocation** (Report Immediately): - **Sudden severe hip pain** (different from expected post-op pain; often described as "catching" or "popping") - **Limb appears shortened**: The affected leg looks shorter than the other (due to flexion and internal rotation) - **Foot is internally rotated**: Toes point inward - **Inability to move the hip** or extreme difficulty with movement - **Audible "clunk"** or feeling of something "giving way" - **Loss of hip stability**: Patient feels insecure, like "something isn't right" - **Swelling and bruising** may appear later If dislocation is suspected, **STOP all activity immediately**, notify the physician, and obtain X-ray confirmation. The dislocation must be reduced urgently (usually under sedation or general anesthesia). **Total Hip Replacement Postoperative Nursing Care**: 1. **Immediate Postoperative Phase** (First 24–48 hours): - **Monitoring**: Vital signs every 4 hours; monitor for fever (sign of infection or DVT) - **Pain management**: Analgesics (opioids, NSAIDs) as ordered; assess pain before movement - **Wound monitoring**: Check dressing for bleeding, drainage, or signs of infection; change dressing per protocol (usually every 24–48 hours) - **Drain management**: Monitor and empty Jackson-Pratt drain (if present); note color and amount of drainage (expect 50–200 mL in first 24 hours); drain usually removed when output is <25 mL per 8-hour shift - **DVT/PE prevention**: - **Sequential compression devices** (SCDs) on legs (except operative leg) to promote venous return - **Anticoagulation**: Start DVT prophylaxis as ordered (may be warfarin, enoxaparin, apixaban, or aspirin depending on protocol) - **Early mobilization**: Begin weight-bearing and walking with assisted devices per physician order and physical therapy - **Ankle exercises**: Encourage ankle pumping and dorsiflexion exercises to prevent DVT - **Leg elevation**: Elevate legs when sitting to reduce swelling - **Hip precautions**: Implement all hip precautions immediately; use abduction pillow - **Positioning**: Supine or on unaffected side only; maintain pillow between legs - **ROM exercises**: Passive ROM by PT; patient performs ankle and knee ROM independently - **Foley catheter care**: If catheter in place (especially in older patients); remove as soon as safe - **Nutrition and hydration**: IV fluids initially; advance diet as tolerated; ensure adequate protein for healing 2. **Early Postoperative Phase** (48 hours to discharge, typically 1–3 days): - **Continued monitoring**: Vital signs, wound, pain, drain output - **Pain management**: Transition from IV to oral analgesics as tolerated - **Mobility progression**: - **Gait training**: Begin assisted ambulation with walker or crutches (per PT protocol) - **Stair climbing**: Teaching and supervised practice (if patient will encounter stairs at home) - **Positioning**: Continue hip precautions; supine or unaffected side; abduction pillow between legs - **Activities of daily living (ADL)**: Adapt for hip precautions (raised toilet seat, use of assistive devices for dressing) - **Avoid hip flexion >90°**: Assist with hygiene and dressing - **Psychosocial**: Assess for anxiety about restrictions; provide reassurance that precautions are temporary - **Discharge planning**: - Assess home safety: remove throw rugs, ensure clear pathways, install grab bars in bathroom, arrange furniture for walker - Arrange home care or PT follow-up if complex needs - Provide discharge instructions (written and verbal) 3. **Home Management** (Weeks 1–8): - **Hip precautions**: Continue for 6–8 weeks (or per surgeon's protocol) - **Activity progression**: Gradual increase in weight-bearing and walking distance as tolerated - **PT/OT follow-up**: Outpatient PT 2–3 times per week for strengthening, ROM, and gait training - **Pain management**: Oral analgesics as needed; may require NSAIDs for swelling - **Wound care**: Keep dry; allow incision to heal (sutures or staples removed at 2 weeks) - **Infection prevention**: Signs to watch for (fever, increased warmth, redness, drainage from incision); report to physician - **DVT prevention**: Continue anticoagulation as prescribed (typically 10–35 days); signs of DVT (calf swelling, warmth, pain) - **Driving**: Usually not permitted until 6 weeks post-op (and patient is comfortable with pain and mobility) **Duration of Hip Precautions**: - **Standard protocol**: 6–8 weeks post-operatively (some surgeons extend to 12 weeks) - **After precautions lifted**: Patient may slowly return to normal activities; full return to function typically by 12 weeks - **Activity restrictions**: Avoid high-impact activities (running, jumping, heavy lifting >10 kg) indefinitely; these can loosen the prosthesis **Common Complications**: 1. **Prosthetic dislocation**: Most common complication (1–5% of cases) - **Prevention**: Hip precautions - **Management**: Emergency reduction (closed reduction or surgical open reduction), then extended hip precautions 2. **Deep vein thrombosis (DVT) and pulmonary embolism (PE)**: - **Incidence**: 0.3–1.7% with prophylaxis - **Prevention**: Anticoagulation, SCD, early mobilization - **Signs**: Calf swelling, warmth, calf pain; chest pain, dyspnea (if PE) 3. **Infection** (periprosthetic infection): - **Incidence**: 1–3% (can occur acutely or years later) - **Prevention**: Prophylactic antibiotics perioperatively, aseptic technique - **Signs**: Persistent pain, fever, drainage, swelling - **Management**: May require washout, antibiotics; in severe cases, prosthesis removal and spacer placement 4. **Hematoma**: Blood collection around surgical site - **Management**: Monitor drain output; may require drainage if large and symptomatic 5. **Leg length discrepancy**: Sometimes unavoidable; usually <1 cm difference 6. **Loosening of prosthesis**: Can occur years after surgery; results in recurrent pain and instability; may require revision surgery **Patient Education** (Critical for Compliance): **Before discharge, the nurse should ensure patient (and caregiver) understands**: 1. **Hip precautions**: Why they are necessary (prevent dislocation), how long they apply (6–8 weeks), and importance of strict adherence 2. **Three main rules** (teach, demonstrate, assess return demonstration): - No hip flexion >90°; use raised toilet seat, no low chairs, no bending forward - No leg crossing; keep legs apart; use abduction pillow at all times - No toes pointing inward; keep toes forward 3. **Signs of dislocation**: What to do immediately (call 911 if unable to move or severe pain) 4. **Signs of infection**: Fever, increased pain, redness, drainage; report to physician 5. **Signs of DVT**: Calf swelling, warmth, calf pain; report to physician 6. **Activity progression**: Increase walking gradually; avoid high-impact activities 7. **PT/OT follow-up**: Importance of attending appointments 8. **Wound care**: Keep dry; notify if signs of infection 9. **Medications**: Continue anticoagulation as prescribed; pain medications as needed 10. **Driving and work**: Discuss realistic timeline for return 11. **Follow-up appointments**: Schedule with surgeon; usually at 2 weeks, 6 weeks, and 3 months **Nursing Diagnosis Examples** for THR patient: - **Risk for Injury** (dislocation) related to post-surgical joint instability as evidenced by early post-operative period - Interventions: Implement hip precautions, use abduction pillow, educate on restrictions, assess understanding - **Acute Pain** related to surgical trauma as evidenced by pain scale and patient verbalization - Interventions: Administer analgesics as ordered, position for comfort, provide cold/heat therapy - **Impaired Physical Mobility** related to surgical restriction and pain as evidenced by limited ambulation - Interventions: Collaborate with PT, assist with ROM, position with pillows, encourage participation in exercises - **Risk for DVT/PE** related to immobility and surgical trauma - Interventions: Apply SCDs, administer anticoagulation, encourage ankle exercises, early mobilization - **Deficient Knowledge** regarding hip precautions and home management - Interventions: Teach hip precautions, provide written handouts, demonstrate and assess return demonstration, involve caregiver